Format

Send to

Choose Destination
Alzheimers Dement. 2018 Apr;14(4):563-575. doi: 10.1016/j.jalz.2018.03.002.

The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.

Author information

1
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
2
Biogen, Cambridge, MA, USA.
3
Alzheimer's Association, Chicago, IL, USA.
4
Alzheimer's Association, Chicago, IL, USA. Electronic address: jhendrix@alz.org.
5
Genentech, Inc., South San Francisco, CA, USA.
6
Pfizer, New York, NY, USA.
7
Cogstate Ltd, Melbourne, Victoria, Australia.
8
Bracket, Wayne, PA, USA.
9
Lundbeck, Deerfield, IL, USA.
10
European Medicines Agency (EMA), London, UK.
11
Mayo Clinic, Jacksonville, FL, USA.
12
University of Kentucky, Lexington, KY, USA.
13
Mount Sinai School of Medicine, New York, NY, USA.
14
Clinical Memory Research Unit, Lund University, Lund, Sweden.
15
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
16
Department of Pathology, Stanford University, Stanford, CA, USA.
17
Janssen Research and Development, San Diego, CA, USA.
18
Hoffmann-La Roche, Inc., Basel, Switzerland.
19
Rush University Medical Center, Chicago, IL, USA.
20
National Institute on Aging, Baltimore, MD, USA.
21
Janssen R&D, Titusville, NJ, USA.
22
VU University Medical Center, Amsterdam, the Netherlands.
23
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
24
Independent Science Writer, Elverson, PA, USA.
25
Eli Lilly and Company, Indianapolis, IN, USA.

Abstract

The Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the "A, T, N System" (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed.

KEYWORDS:

Alzheimer's disease; Amyloid; Biomarkers; Clinical trials; Neurodegeneration; Tau

PMID:
29653607
DOI:
10.1016/j.jalz.2018.03.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center